Pharmaceutical

Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases

The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to Stelara, for treating chronic inflammatory conditions.

Aug 27, 2024 - 04:00
Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases
The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to Stelara, for treating chronic inflammatory conditions.
Read the original article

Tags:

Previous Article

MSD snags European approval for pulmonary arterial hypertension therapy

Next Article

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: CVS’s new drug payment plan won’t lower patients’ prices, experts warn

STAT+: CVS’s new drug payment plan won’t lower patients...

Dec 5, 2023

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal...

Jun 14, 2024

STAT+: Medtronic cancels $738 million acquisition of diabetes tech company EOFlow

STAT+: Medtronic cancels $738 million acquisition of di...

Dec 7, 2023